Tibet Rhodiola Pharmaceutical Holding Company operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tibet Rhodiola Pharmaceutical Holding Company with three other
companies in this sector in China:
China Pioneer Pharma Holdings Ltd
sales of 1.46 billion Chinese Renmimbi [US$211.70 million]
of which 59%
was Products sold via the provision of co-pr),
China NT Pharma Group Co Ltd
(847.73 million Chinese Renmimbi [US$122.84 million]
of which 74%
was Third-party Pharnaceutical Promotion & S), and
Kingworld Medicines Group Limited
(713.55 million Chinese Renmimbi [US$103.40 million]
Tibet Rhodiola Pharmaceutical Holding Company reported sales of 1.38 billion Chinese Renmimbi (US$200.04 million)
December of 2015.
decrease of 17.2%
versus 2014, when the company's sales were 1.67 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 29.9% decline
in Pharmaceutical Business Trade, from 1.23 billion Chinese Renmimbi to 860.62 million Chinese Renmimbi.
However, these declines were partially offset by the increase in sales of
Pharmaceutical Manufacturing Industry (up 18.8% to 515.11 million Chinese Renmimbi)